JPS5959611A - Stable solubilized composition of riboflavin butyrate and its preparation - Google Patents
Stable solubilized composition of riboflavin butyrate and its preparationInfo
- Publication number
- JPS5959611A JPS5959611A JP16916382A JP16916382A JPS5959611A JP S5959611 A JPS5959611 A JP S5959611A JP 16916382 A JP16916382 A JP 16916382A JP 16916382 A JP16916382 A JP 16916382A JP S5959611 A JPS5959611 A JP S5959611A
- Authority
- JP
- Japan
- Prior art keywords
- sorbitan
- oil
- boflavin
- ethanol
- rough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical group CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000003921 oil Substances 0.000 claims abstract description 44
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims abstract description 39
- 239000003925 fat Substances 0.000 claims abstract description 29
- 239000002253 acid Substances 0.000 claims description 29
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 13
- 239000001593 sorbitan monooleate Substances 0.000 claims description 13
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 13
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 230000002402 anti-lipaemic effect Effects 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 206010047612 Vitamin B2 deficiency Diseases 0.000 abstract 1
- 201000007590 ariboflavinosis Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000004223 riboflavin deficiency Diseases 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 39
- 235000019197 fats Nutrition 0.000 description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 239000004094 surface-active agent Substances 0.000 description 12
- -1 sorbitan fatty acid ester Chemical class 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 235000019485 Safflower oil Nutrition 0.000 description 6
- 239000003813 safflower oil Substances 0.000 description 6
- 235000005713 safflower oil Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 235000014593 oils and fats Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 241001125048 Sardina Species 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 235000019512 sardine Nutrition 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241001517013 Calidris pugnax Species 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 101150093826 par1 gene Proteins 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】 成物およびその製造法に関する。[Detailed description of the invention] related to products and their manufacturing methods.
ラフ酸すボフラビンは、ビタミンB,(リボフラピン〕
が油脂に不溶、水に難溶でかつにがみを有しているので
、ラフ酢とのエステル誘導体とすることにより油脂への
溶解性を改良したもので、高脂質血症、ビタミンB,欠
乏症の予防および治療に広く使用されている。Ruff acid boflavin is vitamin B, (riboflapine)
is insoluble in fats and oils, poorly soluble in water, and has a bitter taste, so it is made into an ester derivative with rough vinegar to improve its solubility in fats and oils, and is effective against hyperlipidemia, vitamin B, Widely used to prevent and treat deficiency diseases.
一方、本発明者等は、従来よりオレイン酌、リノール酸
、リルン酸、エイコサペンタエン酸等の不飽和脂肪酸を
多量に含有する油脂に抗脂血作用かあることか知られて
いることから、これらの不飽和脂肪酸を含有する油脂に
ラフ酸すボフラビンを添加することにより、これら不f
IQ和脂肪酸が有する抗脂血作用とラフ酸すボフラビン
の抗高脂血症の予防、・治療効果(抗脂血作用)との相
加効果を期待して、ラフ酸すボフラピンと油脂のof溶
化組成物の研究を行なった。On the other hand, the present inventors have discovered that oils and fats containing large amounts of unsaturated fatty acids such as oleic acid, linoleic acid, lylunic acid, and eicosapentaenoic acid have been known to have antilipemic effects. By adding rough acid boflavin to fats and oils containing unsaturated fatty acids, these unsaturated fatty acids can be removed.
In anticipation of the additive effect of the antilipidemia effect of IQ fatty acids and the antihyperlipidemic preventive and therapeutic effects (antilipidemia effect) of rough acid boflavin, we have developed the combination of rough acid boflapine and oil. A study of solubilized compositions was conducted.
しかし、ラフ酸すボフラビンの食用油脂・\の溶解度は
必ずしも高いものではなく、ピ゛タミン第33巻5号4
66頁に示される如< ?ll] 11旨【こタ4して
0.2(w/w)%が限度て°ある。However, the solubility of rough acid boflavin in edible oils and fats is not necessarily high;
As shown on page 66. ll] 11 [There is a limit of 0.2 (w/w)%.
能力、桑効を期待してラフ酸すボフラビンを革Y11投
り゛する場合、通常成人では1115〜120 mgを
2〜3回に分けて投lj、することが好ましい。When administering rough-acided boflavin to the skin in hopes of improving performance and mulberry effects, it is usually preferable for adults to administer 1115 to 120 mg divided into 2 to 3 doses.
しかし、この11kを油脂l\溶解させるためには少な
くとも2.5〜60gの油脂が必用であり、このようか
多1.)の油脂を一般に用い#″)れるカプセル名′に
旧人した・場合、服用すし服用同数か増大してしまい、
服用者にとってはtl’i 3.Itで・f・便を強い
るものである。However, in order to dissolve this 11k of oil and fat, at least 2.5 to 60g of oil and fat are required. ) oils and fats are commonly used in the capsule name ').
tl'i for those taking 3. It forces you to ・f・ stool.
従って、ラフ酸すボフラビンのi+T fW化紹成物を
5H7るには、ラフ酸すボフラヒンを不飽和脂肪酸を含
有する油脂に高61度に溶解させることが屯凹になるの
である。Therefore, in order to prepare the i+T fW introduction product of rough acid boflavin, it is necessary to dissolve rough acid boflavin in oil and fat containing unsaturated fatty acids at a temperature of 61 degrees Celsius.
本発明者笠はに記問題点を克服すべく、ラクrl’+リ
ボフラビンを油脂に溶解させる方法を鋭、0゜7σ1究
の結果、本発明を完成したものである。In order to overcome the above-mentioned problems, the inventor of the present invention has completed the present invention as a result of extensive research into a method for dissolving Rl'+riboflavin in fats and oils.
すなわち、本発明はラクMリボフラビンと、ソルビタン
セスキオレートまたはソルビタンモノオレートあるいは
ソルビタンセスキオレートとソルビタンモノオレー1・
どの混合物と、エタノールと、油脂とからなることを#
!jj71とする安定なラフ酸すボフラビンiir f
W化組成物、およびラフ削りボフラピンを、ソルビタン
セスキオレートまたはソルビタンモノオレー1・あるい
はソルビタンセスキオレートとソルビタンモノオレート
どの混合物、およびエタノールに溶解した後、該溶解物
を油脂中に溶解させることを特徴とする安定なラフ削り
ボフラピン1−1f濱化相成物の製造法にかかるもので
ある。That is, the present invention provides LacM riboflavin, sorbitan sesquiolate or sorbitan monooleate, or sorbitan sesquiolate and sorbitan monoole 1.
#Which mixture consists of ethanol and fat?
! Stable rough acid boflavin iir f as jj71
The W composition and rough shaved bofrapine are dissolved in sorbitan sesquiolate, sorbitan monooleate 1, or a mixture of sorbitan sesquiolate and sorbitan monooleate, and ethanol, and then the dissolved product is dissolved in fats and oils. The present invention relates to a method for producing a stable rough-shaving Bofrapin 1-1f atomized phase composition.
まず、本発明の安定なラフ酸すボフラビン町溶化組成物
の組成を決定するために?■なった試;険についで説明
する。First, to determine the composition of the stable rough acid boflavin town solubilized composition of the present invention? ■The trial that became; I will explain the risk next.
多+4のたとえばl (w/w)%以上のラフ酌すボフ
ラビンを油脂へ溶解させるための方法として、溶解補助
剤(たとえば、エタノール、プロピレンクリコール、ク
リセリン、ボリエナレン々リコール、中鎖脂肪酸クリセ
ライト等)を用いる方法、非イオン性界面活性剤(たと
えは、ソルビタン脂肪酸エステル、クリセリン脂肪酸エ
ステル、プロピレンクリコール脂肪酸エステル、ショ糖
脂肪酸エステル等)を用いる方法、および+tif記溶
解補助剤と…I記非イオン性界而面性剤の両者を用いる
方法について行ない、溶解状態及び安定性について観察
した。As a method for dissolving 1 (w/w) % or more of boflavin into fats and oils, a solubilizing agent (for example, ethanol, propylene glycol, chrycerin, polyenalene glycol, medium chain fatty acid chrycerite, etc.) may be used. ), a method using a nonionic surfactant (for example, sorbitan fatty acid ester, chrycerin fatty acid ester, propylene glycol fatty acid ester, sucrose fatty acid ester, etc.), and a method using +tif solubilizing agent and...I non-ionic surfactant. A method using both ionic interfacial agents was conducted, and the state of dissolution and stability were observed.
すなわち、ラフ酸すボフラビン200mgに溶解補助剤
(エタノール、プロピレングリコール、クリセリン、ポ
リエチレングリコール400、カプリル酌トリグリセラ
イド)3mQおよび/または界面活性剤(ソルビタント
リオレートHLB1.8、ソルビタンセスキオレー1−
HLB3.7、ソルビタンモノオレートHL B 4−
3、ソルビタンモノステアレートHLB4.7. ソ
ルヒタンモノバルミテ−1−HLB6−7、ソルビタン
モノオレー1− HL B8.6 、クリセリンモノオ
レートHLB2.8.プロピレングリコールモノステア
レー1− HL B3.5 、ショ糖脂肪酸エステルH
LB2−0.5・7)4gを力11え、70°Cの水7
谷1]1で力117i111攪拌した後水冷した。溶解
したものについては溶解物をサフラワー油20gに加え
41j打し、((温、o ’cおよび40°Cで、4週
間保イr後その安定性を観察した。その結果を第1表に
示す。That is, 200 mg of rough acid boflavin, 3 mQ of solubilizing agents (ethanol, propylene glycol, chrycerin, polyethylene glycol 400, caprylic triglyceride) and/or surfactants (sorbitan triolate HLB 1.8, sorbitan sesquiole 1-
HLB3.7, sorbitan monooleate HL B 4-
3. Sorbitan monostearate HLB4.7. Sorhitan monobalmite-1-HLB6-7, Sorbitan monooleate-1-HLB8.6, Chrycerin monooleate HLB2.8. Propylene glycol monostearate 1-HL B3.5, sucrose fatty acid ester H
LB2-0.5・7) 4g with force 11 and 70°C water 7
The mixture was stirred with a force of 117 x 111 at a temperature of 1] 1 and then cooled with water. The dissolved product was added to 20 g of safflower oil, beaten for 41 hours, and kept at room temperature, o'clock and 40°C for 4 weeks, and then its stability was observed. The results are shown in Table 1. Shown below.
第 1 表
A いずれの条件においても透明溶液(安定)であっ
た。Table 1 A A transparent solution (stable) was obtained under all conditions.
B いずれかの条件において分離が認められた。B: Separation was observed under any of the conditions.
C: いずれかの条件において濁りあるいは沈殿が認め
られた。C: Turbidity or precipitation was observed under any of the conditions.
D: 不溶であるので油脂へは加えなかった。D: It was not added to fats and oils because it was insoluble.
この結果から明らかなようにエタノールとソルビタンセ
スキオレートあるいはエタノールとソルビタンモノオレ
ートを組み合わせて用いた場合にのみ、油脂中に溶解す
ることができかつ長期間保存しても安定に保持すること
ができた。As is clear from these results, only when ethanol and sorbitan sesquiolate or ethanol and sorbitan monooleate were used in combination could they be dissolved in fats and oils and maintained stably even during long-term storage. .
そして、その池の場合には、ラフ酷すボフラビンを透明
に溶解することができないか、あるいは透明に溶解でき
てもラフ酸すボフラビンを溶かした後油脂に加えると、
ただちにまたは経時的に油脂との分離あるいはラフ醜す
ボフラビンの晶出が生じてしまい、油脂への可溶化およ
び安定化が困鮪であった。In the case of that pond, either the rough acidic boflavin cannot be dissolved transparently, or even if it can be dissolved transparently, if the rough acidic boflavin is dissolved and then added to the fat.
Immediately or over time, boflavin separates from fats and oils or crystallizes out, making it rough and ugly, making it difficult to solubilize and stabilize it in fats and oils.
従って、本発明の安定なラフ酸すボフラビンr+f溶化
組成物の組成としては、ラフ酸すボフラビンのほかソル
ビタンセスキオレート、ソルビタンモノオレー1・等の
界面活性剤、エタノールおよび油脂があげられる。Therefore, the composition of the stable rough acid boflavin r+f solubilized composition of the present invention includes, in addition to rough acid boflavin, surfactants such as sorbitan sesquiolate and sorbitan monoole 1., ethanol, and fats and oils.
本発明において使用する界面活性剤はソルビタンセスキ
オレート[たとえば、アラッセル83(花王アトラス社
製〕〕 または、ソルビタントリオレート〔たとえば、
スパン80(花王ア)・ラス社製)〕あるいは両者を混
合したものであるか、必要に応じてこれに他の界面活性
剤の1種または2種以」二を適宜混合することもできる
。The surfactant used in the present invention is sorbitan sesquiolate [for example, Arasel 83 (manufactured by Kao Atlas Co., Ltd.]) or sorbitan triolate [for example,
Span 80 (manufactured by Kao A.R.S. Co., Ltd.)] or a mixture of both, or one or more other surfactants may be appropriately mixed therewith as required.
他の界面活性剤としてはソルビタン脂肋酌エステル類〔
たとえば、ソルビタントリオレート、ソルビタンモノラ
ウレート等〕、クリセリン脂肪酸エステル類〔たとえば
、グリセリンモノオレー1・等)、プロピレングリコー
ル脂肪酸エステル類(たとえば、プロビレクリコールモ
ノステアレート等)、レシチン等が挙げられる。Other surfactants include sorbitan fat esters [
For example, sorbitan triolate, sorbitan monolaurate, etc.], chrycerin fatty acid esters (e.g., glycerin monoole 1, etc.), propylene glycol fatty acid esters (e.g., provilleclicol monostearate, etc.), lecithin, etc. .
油脂はサフラワー油、コマ油、タイズ油、メンシラ油、
ナタネ油、キヨウニン油、ヌカ油、ラッカセイ油、オリ
ーブ油、ツバキ油、ヒマシ油、ヤシ油、パーム油、トウ
モロコシ油、小麦肝ダ油、イワシ油、タラカン油等の食
用油111tが使用可能であり、不飽和脂肪酸を多量に
含むものか好ましい。Fats include safflower oil, sesame oil, soybean oil, mensilla oil,
111 tons of edible oils such as rapeseed oil, corn oil, bran oil, peanut oil, olive oil, camellia oil, castor oil, coconut oil, palm oil, corn oil, wheat liver oil, sardine oil, taracan oil, etc. can be used, Preferably, it contains a large amount of unsaturated fatty acids.
本発明の安定なラフ酸すボフラビン町溶化組成物を製造
する際は、ラフ酸すボフラビ゛ンにソルビタンセスキオ
レートまたはソルビタンモノオレー1・あるいはソルビ
タンセスキオレートとソルビタンモノオレートとの混合
物、およびエタノールを加え、加?1.t ffi拌し
て溶解させた後冷却し、該溶解物を油脂中に攪拌溶解す
る。When producing the stable rough acid boflavin-soluble composition of the present invention, sorbitan sesquiolate, sorbitan monoole 1, or a mixture of sorbitan sesquiolate and sorbitan monooleate, and ethanol are added to the rough acid boflavin. Addition, addition? 1. t ffi After stirring and dissolving, cool and stir and dissolve the melted material in fats and oils.
本発明において使用するエタノールの量および界面活性
剤(ソルビタンセスキオレートまたはソルビタンモノオ
レートあるいは両者の混合物)の檄は図に示す通りであ
る。図はラフ酸すボフラビン1重量部をサフラワー油1
00 Qi呈部に+7f W化および安定化させるため
に使用するエタノールの量と界面活性剤の量の関係を示
す図であり、それぞれはOf溶化組成物(ラフ酸すボフ
ラビン、エタノール、界面活性剤、油脂等からなる組成
物)に対する(wへ〕%で示しである。The amount of ethanol and the amount of surfactant (sorbitan sesquiolate or sorbitan monooleate or a mixture of both) used in the present invention are as shown in the figure. The figure shows 1 part by weight of rough acid boflavin and 1 part by weight of safflower oil.
00 is a diagram showing the relationship between the amount of ethanol and the amount of surfactant used for +7f W conversion and stabilization in the Qi-exposing part, and each of , a composition consisting of oils and fats, etc.).
+2f中人はラフ酸すボフラビンを可溶化でき、かつ、
室温、0゛Cおよび40°Cて6力月間保イrF)、い
ずれの条件でも安定である範囲、他はいずれかの条件に
おいて分離あるいは沈殿を生じる範囲を示す。使用する
界面活性剤の量はn(溶(L 11酸物に74して5F
’w/w)%以1:であればよい。しかし、安全+11
をJ +爬すると極力少;Cf用いることか1−!まし
い。+2f Chuunin can solubilize rough acid boflavin, and
Storage at room temperature, 0°C, and 40°C for 6 months (rF), the range is stable under any of the conditions, and the others are the ranges where separation or precipitation occurs under any of the conditions. The amount of surfactant used is
'w/w)% or more 1: is sufficient. However, safety +11
If you use J+, you should use as little as possible; use Cf or 1-! Delicious.
使用するエタノールのtiJIは界面粘f1剤の11(
により適宜増減できるが、II丁溶化組成物に対し約9
%か好ましい。エタノールの;tlか多才きると分用を
生じ、少なすぎるとにこりあるいは沈殿を牛しる。The tiJI of the ethanol used is 11 (
The amount can be increased or decreased as appropriate, but the amount of
% is preferable. Too much ethanol will cause dilution, and too little will cause smearing or precipitation.
本発明により製造されるラフ1駿リボフラを巳ン呵溶化
相酸物は必四に応じて脂溶+11桑物、脂溶=l’lビ
タミン等を加えることもでき、軟カプセル斉りどして1
史月Jするのが“4.)にtlfましい。Depending on the needs, fat-soluble + 11 mulberry substances, fat-soluble = l'l vitamins, etc. can be added to the rough 1-sun ribofura soluble phase acid produced by the present invention, and soft capsules can be added. te1
Fumizuki J is like “4.)”.
以り述・\たように本発明によれば、従来油脂に対し0
.2(w/w)%か限度であったラフ酸すボフラヒンの
j容解ノ負を1 (w/w)%以1.にまC引きトし)
ることかてさかつ長期間安定に保持することかでき゛る
。このように、不飽和脂肪酸を含イ1する油脂にラフ酸
すボフラビンを+:’6 h″′:j度に溶解すること
かできかつ長期間安定に保1.′Jすることカイできる
ので、ラフ酸すボフラビンの葉効Tv1をJ&油脂に溶
解して粁1−1投lj、する場合、油脂量を大幅に誠少
させることかでき、服用が容易となる。As described below, according to the present invention, compared to conventional oils and fats,
.. 2 (w/w)% or less of rough acid bofurahin, which was the limit, was reduced to 1 (w/w)% or more. Nima C pull)
In fact, it can be maintained stably for a long period of time. In this way, it is possible to dissolve boflavin by rough acid in fats and oils containing unsaturated fatty acids to +:'6h''':j degrees and to keep it stable for a long period of time. When the leaf effect Tv1 of rough acid boflavin is dissolved in J&oil and administered as 1-1 lj, the amount of oil and fat can be significantly reduced, making it easy to take.
さらに、界面粘ヂ1剤を系油した油1指は粁11投すし
た場合Ann、 Intcrn、Mcd、29.1 (
1948)等に記載のあるように消化吸収がよくなるこ
とか知I:)れでいる。また、ラフ酸すボフラビンを油
脂に高話度に溶解したことにより該油脂と共に腸’?≧
7/i膜かC)吸収されやすくなり、錠hす、顆おシ等
の剤形で経11投すした場合に比べ、吸++y 1lJ
)率が高まる。Furthermore, if 1 finger of oil containing 1 interfacial viscosity agent is poured into 11 pieces of oil, Ann, Intcrn, Mcd, 29.1 (
1948), it is well known that it improves digestion and absorption. In addition, by dissolving rough acid boflavin in fats and oils to a high degree of talk, it has been found that the intestines' ≧
7/i membrane C) It is easily absorbed, and the absorption rate is 1 lJ compared to when administered orally in the form of tablets, capsules, etc.
) rate increases.
従って、ラフ酸すポフラヒンをイζ飽和脂肪酸を含有す
る油1指と共に粁11投すすることて゛1向者の抗脂血
作用を4jtゼで発揮することかできる。Therefore, it is possible to exert the anti-lipidemia effect of 4Jts by administering rough acid poflahin together with 1 finger of oil containing saturated fatty acids.
また、本発明の製造法によれは、lt 1119的八千
の容易な特産の原料を用いて大:+)’I’、 rMす
ることかできる。In addition, according to the production method of the present invention, it is possible to produce large amounts of 1119% by using easily available special raw materials.
以上、す!施例により本発明をす体重に説明する。That’s it! The invention will be illustrated by way of example.
実施例
う77酌リボフラビン200 mlBにエタノール3
mQ〔11丁溶化用成酸物対して9.2(w/w)%〕
および界面活性剤((a)〜(f))4g (可溶化組
成物に対して15(w/v)%〕を加え、70゛Cの水
浴中で5分間加温攪拌し溶解させた後水冷した。該溶解
物をサフラワー油208に加え攪拌し、室温、0°Cお
よび40°Cで保存し、6力月間その安定性を観察した
。Example 77 200 ml of riboflavin and 3 ethanol
mQ [9.2 (w/w)% based on 11 solubilizing oxides]
and 4 g of surfactants ((a) to (f)) (15 (w/v)% based on the solubilized composition) were added and dissolved by heating and stirring in a 70°C water bath for 5 minutes. The solution was cooled with water.The resulting solution was added to safflower oil 208, stirred, and stored at room temperature, 0°C and 40°C, and its stability was observed for 6 months.
界面活性剤((a)〜(f))はつきのとおりである。The surfactants ((a) to (f)) are as follows.
(a)ソルビタンヤスキオレート ソルビタントリオレート(11) (b)ソルビタンモノオレート。(a) Sorbitan jasquiolate Sorbitan triolate (11) (b) Sorbitan monooleate.
クリセリンモノオレート〔12〕 (c)ソルビタンセスキオレート・ ソルビタンモノオレー1−(1:1) (d)ソルビタンセスキオレート: ソルビタンモノラウレート(11) (c)ソルピタンモノオレート: プロピレングリコールモノステアレ ート(l : 1) (f)ソルビタンモノオレート。Chrycerin monooleate [12] (c) Sorbitan sesquiolate Sorbitan monoole 1-(1:1) (d) Sorbitan sesquiolate: Sorbitan monolaurate (11) (c) Solpitan monooleate: Propylene glycol monosteare root (l: 1) (f) Sorbitan monooleate.
ソルビタンセスキオレート
グリセリンモノオレート(1・1:1)その結果、いず
れの界面活性剤でもor溶化でき、いずれの条件におい
ても安定に保持された。Sorbitan sesquiolate glycerol monooleate (1.1:1) As a result, any surfactant could be dissolved and maintained stably under any conditions.
以上の結果から明らかなように、ソルビタントリオレー
トグリセリンモノオレート、プロピレングリコールモノ
ステアレート等は単独ではtiT ’m化および安定化
できないが、ソルビタンセスキオレートまたはソルビタ
ンモノオレートあるいは両者の混合物に混合すれば使用
できる。As is clear from the above results, sorbitan triolate, glycerol monooleate, propylene glycol monostearate, etc. cannot be converted into TiT'm and stabilized alone, but when mixed with sorbitan sesquiolate, sorbitan monooleate, or a mixture of the two, Can be used.
実施例
ラフ削りホフラピン200mgにエタノール3 mQ〔
可溶化組成物に対してg、2(w/w)%〕及びソルビ
タンモノオレー)4g(”T溶化組成物に対して15(
w/v)%〕を加え、70°Cの水浴中で5分間加温攪
拌し、溶解させた後水冷した。該溶解物を油脂((a)
〜(p))20gに加え攪拌し室温、0°Cおよび40
°Cで保存し、6力月間その安定性を観察した。Example: 200 mg of rough shaved hofrapine and 3 mQ of ethanol [
g, 2 (w/w)%] for solubilized composition and sorbitan monoole) 4 g (15% for solubilized composition)
w/v)%] was added, heated and stirred in a 70°C water bath for 5 minutes to dissolve, and then cooled with water. The dissolved matter is mixed with oil ((a)
~(p)) 20g and stirred at room temperature, 0°C and 40°C.
It was stored at °C and its stability was observed for 6 months.
油脂((a)〜(p))はつきのとおりである。The fats and oils ((a) to (p)) are as shown.
ra)コマ油、(’b)タイズ油、(’c)メンジッ油
、(d)ナタネ油、(c)キョウニン油、(f)ヌカ油
、(’g)ラッカセイ油、(h)オリーブI′I11、
(i)ツバキ油、N)ヒマシ油、(k)ヤシ油、(1)
パー1\油、(m)トウモロコシ油、(1)イワシ油、
(o)タラカン油、(p)小麦胚芽油。ra) Sesame oil, ('b) Tize oil, ('c) Menzi oil, (d) Rapeseed oil, (c) Kyonin oil, (f) Bran oil, ('g) Peanut oil, (h) Olive I' I11,
(i) Camellia oil, N) Castor oil, (k) Coconut oil, (1)
Par 1\ oil, (m) corn oil, (1) sardine oil,
(o) Tarakan oil, (p) wheat germ oil.
その結果、いずれの油脂にも可溶化でき、いずれの条件
においても安定に保持された。As a result, it was able to be solubilized in any fat or oil and was stably maintained under any conditions.
実施例3
(1) ラフ醜すボフラビン200g、y−オリザノ
ール200gにエタノール5Qおよびソルビタンモノオ
レート3 kgを加え、約70°Cで加温1(!11’
L溶解させた後冷却した。Example 3 (1) Ethanol 5Q and sorbitan monooleate 3 kg were added to 200 g of boflavin and 200 g of y-oryzanol, and heated at about 70°C.
After dissolving L, it was cooled.
(2) イワシ油30kgに酢酸d−α−トコフェロ
ール2kgを加え攪拌した。(2) 2 kg of d-α-tocopherol acetate was added to 30 kg of sardine oil and stirred.
(3) (1)、(2)を混合し攪I′P後、常法で
処理して軟カプセル剤とした。(3) (1) and (2) were mixed, stirred I'P, and treated in a conventional manner to form soft capsules.
実施例4
(1) ラフ酸すボフラビン200g、ウルソデオキ
シコール酸300g、y−オリザノール200g、エタ
ノール5Q、ソルビタンモノオレート1.5kgおよび
クリセリンモノオレー1・3 kgを混合し、約70°
Cて加温攪j’+ L溶解させた後冷却した。Example 4 (1) 200 g of rough acid boflavin, 300 g of ursodeoxycholic acid, 200 g of y-oryzanol, 5Q ethanol, 1.5 kg of sorbitan monooleate and 1.3 kg of chrycerin monooleate were mixed and heated at about 70°.
The mixture was heated and stirred at C to dissolve it, and then cooled.
(2)酢酸d−α−トコフェロール200 g、大豆レ
シチン10kg、ソルビタントリオレー1□ 2 kg
およびサフラワー油20.2kgを混合した。(2) 200 g of d-α-tocopherol acetate, 10 kg of soybean lecithin, 1□ 2 kg of sorbitan triole
and 20.2 kg of safflower oil were mixed.
(3)(りと(2)を混合攪拌後、常法で軟カプセル剤
とした。(3) (After mixing and stirring Rito (2), soft capsules were prepared in a conventional manner.
実施例3および実施例4の本発明の可溶化組成物は室温
、O”Cおよび40°Cで6力月経過後も安定に保持さ
れた。The inventive solubilized compositions of Examples 3 and 4 remained stable at room temperature, O''C and 40°C after 6 months.
図はラフ酸すボフラビン1重量部をサフラワー油100
重量部に可溶化及び安定化させるために使用するエタノ
ールの量と界面活+1剤の量の関係を示す図であり、横
軸は界面粘性剤のjil、、縦軸はエタノールのrj髪
を小し、図中Aはラフ醜すボフラビンを可溶化及び安定
化できる範囲を示す。The figure shows 1 part by weight of rough acid boflavin and 100 parts by weight of safflower oil.
It is a diagram showing the relationship between the amount of ethanol used for solubilization and stabilization in parts by weight and the amount of surfactant +1 agent, where the horizontal axis is the surface viscosity agent, and the vertical axis is the amount of ethanol rj. In the figure, A indicates the range in which boflavin, which is rough and ugly, can be solubilized and stabilized.
Claims (1)
1・またはソルビタンモノオレートあるいはソルビタン
セスキオレートとソルビタンモノオレー1〜との混合物
と、エタノールと、油脂とからなることを特徴とする安
定なラフ酸すボフラビン町溶化相成物。 2〕 ラフ酸すボフラヒンを、ソルビタンセスキオレー
トまたはソルビタンモノオレ=1・あるいはソルビタン
セスキオレー1・とソルビタンモノオレー1・どの混合
物、およびエタノールにifr解した後、該溶解物を油
脂中に溶解させることを特(敢とする安定なラフ酸すボ
フラビンII丁溶化M1成物の製造法。[Claims] ■) It is characterized by consisting of rough acid boflavin, sorbitan sesquiolet 1 or sorbitan monooleate, or a mixture of sorbitan sesquioleate and sorbitan monoole 1 to 1, ethanol, and oil or fat. Stable rough acid boflavin town solubility phase composition. 2] After dissolving rough acid bofurahin in sorbitan sesquiolate or sorbitan monoole=1, or a mixture of sorbitan sesquiolete 1 and sorbitan monoole 1, and ethanol, the dissolved product is dissolved in fats and oils. A method for producing a particularly stable rough acid boflavin II solution M1 product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16916382A JPS5959611A (en) | 1982-09-28 | 1982-09-28 | Stable solubilized composition of riboflavin butyrate and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16916382A JPS5959611A (en) | 1982-09-28 | 1982-09-28 | Stable solubilized composition of riboflavin butyrate and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5959611A true JPS5959611A (en) | 1984-04-05 |
| JPH0149245B2 JPH0149245B2 (en) | 1989-10-24 |
Family
ID=15881433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16916382A Granted JPS5959611A (en) | 1982-09-28 | 1982-09-28 | Stable solubilized composition of riboflavin butyrate and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5959611A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187620A (en) * | 1984-10-05 | 1986-05-06 | Nisshin Kagaku Kk | Transparent compounded drug preparation of vitamin b2 butyric acid ester for soft capsule |
| JPS6293232A (en) * | 1985-10-21 | 1987-04-28 | Taisho Pharmaceut Co Ltd | Composition containing riboflavin acetate |
-
1982
- 1982-09-28 JP JP16916382A patent/JPS5959611A/en active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187620A (en) * | 1984-10-05 | 1986-05-06 | Nisshin Kagaku Kk | Transparent compounded drug preparation of vitamin b2 butyric acid ester for soft capsule |
| JPS6293232A (en) * | 1985-10-21 | 1987-04-28 | Taisho Pharmaceut Co Ltd | Composition containing riboflavin acetate |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0149245B2 (en) | 1989-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7265264B2 (en) | Method for selective extraction of cannabinoids from plant sources | |
| US5998396A (en) | Oil solubilized solutions and foods containing phytosterols and process for their production | |
| US3085939A (en) | Oil-in-water emulsion for oral administration, and process for preparation | |
| DE69818704T2 (en) | METHOD FOR IMPROVING THE ABSORPTION AND TRANSPORT OF LIPID-SOLUBLE COMPOUNDS BY MEANS OF STRUCTURED GLYCERIDES | |
| DE69707669T2 (en) | ORAL PHARMACEUTICAL COMPOSITIONS WITH SEXUAL HORMONES | |
| JP4209467B2 (en) | Formulation composition for oral administration | |
| DE69034181T2 (en) | Capsule containing a dioxabicyclo (3.3.0) octane | |
| EP1313447A1 (en) | Palatable oral coenzyme q liquid | |
| EP2444081A1 (en) | A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol | |
| CN100367951C (en) | Butylphthalide Intravenous Emulsion and Its Application | |
| JP2002541111A (en) | Formulation containing testosterone undecanoate and castor oil | |
| JPS61500432A (en) | Easily absorbable fatty acid emulsion | |
| JP6903410B2 (en) | Oil-in-water emulsified composition | |
| CN105617133B (en) | Composite peony seed oil self-emulsifying system composition and preparation method thereof | |
| EP1177729B1 (en) | Pharmaceutical and food compositions containing "wood alcohols" or "wood sterols" useful for lowering serum cholesterol | |
| WO2007067593A2 (en) | Self-emulsifyng formulations of cetp inhibitors | |
| TWI598093B (en) | A stable composition containing high concentiation coenzyme q10 | |
| JPH09502196A (en) | Usage of vegetable oils | |
| JPH0741422A (en) | Method for solubilizing gamma-oryzanol in water | |
| JPH07188027A (en) | Stable hydrocortisone butyrate containing cream | |
| JPH10179086A (en) | Oil solubilized solution, food and drink containing plant sterol, and method for producing the same | |
| CN103859395B (en) | A kind of ubiquinone of high-absorbility 10self-emulsifying drug delivery system and preparation method thereof and application | |
| JPH01135715A (en) | Stable aqueous solutions of fat-soluble substances | |
| JP5300038B2 (en) | Topical skin preparation | |
| JP2005047851A (en) | Ubidecarenone-containing composition |